Syndecan-1/CD138 Expression in Triple Negative Breast Carcinoma.
Abbie L Husman, Amy L Adams, Cynthia Cohen, Andrew J Page, Harold C Sullivan, Gabriela M Oprea. Emory University, Atlanta, GA
Background: Syndecan-1/CD138 (Sdc1), a transmembrane heparan sulfate proteoglycan, modulates many biologic processes relevant to tumor progression, including cell proliferation, adhesion, migration, and angiogenesis. Altered Sdc1 expression has been described in several different tumor types; in breast cancer, increased expression confers an unfavorable prognosis with poor response to traditional chemotherapy regimens. We examined the expression of Sdc1 in triple negative breast cancer (TNBC) from African American (AA) and Caucasian (CS) patients to determine if variable expression correlates with the clinicopathologic and survival discrepancies in these patient populations.
Design: Invasive TNBC negative for ER, PR and Her-2 (scored as 0, 1, or 2+ with no amplification by FISH) were included. Tissue microarrays (TMAs), constructed with two 1 mm cores from each carcinoma, were stained with monoclonal antibody to Sdc1. Immunostain was scored for intensity (0-3) and tumor cells staining (%). Tumors that scored ≥1 for intensity with ≥5% tumor cells staining were considered positive. Sdc1 expression was compared in AA and CS patients in reference to clinicopathologic parameters (age, tumor size, tumor grade, angiolymphatic invasion [ALI], lymph node status, distant metastasis) and follow-up data (recurrence, died of disease [DOD]).
Results: Of a total 122 patients, 70 were AA and 52 were CS. Sdc1 was positive in 81.1% of TNBC, with no statistical difference between AA and CS cohorts (AA=77.1%, CS=86.5%, p=0.189).
|Syndecan (+)||Syndecan (-)|
|Age (mean, yrs)||73.5||58.2||0.630||48.7||59.0||0.04|
|Tumor Size (mean, cm)||3.46||2.38||0.622||3.8||1.0||<0.01|
|Grade III (%)||77.8||71.1||0.492||87.5||71.4||0.557|
|>1 LN Involvement (%)||44.2||31.0||0.207||31.3||16.7||0.634|
|Distant Metastasis (%)||34.0||26.3||0.486||25.0||16.7||1.000|